{"groups":[{"description":"Patients receive crizotinib 250 mg PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nCrizotinib: Given PO","id":"FG000","title":"Treatment (Crizotinib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Complicating disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"comment":"All 4 patients enrolled were eligible and treated in the arm.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"comment":"Treatment continued until disease progression or intolerability.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol G, patients had to have an ROS1 translocations (other than patients with non-small cell lung cancer).","recruitmentDetails":"Subprotocol G was activated on August 12, 2015. A total of 5 patients were assigned to this arm after screening, 2 from screening cohort and 3 from outside assay. Of the 5 patients, 4 patients were enrolled to arm G between August 2015, and September 2018."}